Acrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-13 · Company identity, CIK, ticker, exchange, headquarters, and filing sequence.SEC APISEC companyfacts JSON2026-05-13 · XBRL financial fact cross-check support.SEC filingQ1 2026 Form 10-Q2026-05-13 · Latest financial statements, cash and investments, operating cash use, runway, pipeline status, risks, and ATM sale.SEC-filed releaseQ1 2026 earnings release2026-05-13 · Q1 results, cash runway, ACR-368 catalyst timing, ACR-2316 update, ACR-6840 timing, and management commentary.SEC filingFY2025 Form 10-K2026-03-19 · Business model, AP3 platform, pipeline, license obligations, employees, facilities, risk factors, and FY2025 financials.SEC-filed releaseFY2025 results release2026-03-19 · FY2025 results, ACR-368 ESGO update, ACR-2316 early data, CLIA lab, and 2026 milestones.SEC-filed presentationMarch 2026 corporate presentation2026-03-19 · Pipeline map, AP3 platform description, trial arms, development path, and milestone framing.SEC filingQ1 2026 Form 8-K2026-05-13 · Filing wrapper for Q1 2026 earnings release.SEC filing2026 proxy statement2026-04-30 · Annual meeting, board, executive leadership, beneficial ownership, and related-party transaction policy.